| 4/23/2012 | CVLM | L-1 Identity calls all $90.99 million of 3.75% convertibles due 2027
|
| 7/26/2011 | CV | L-1 Identity amends conversion terms of 3.75% notes on Safran merger
|
| 6/22/2011 | BKCV | S&P cuts L-1 Identity
|
| 2/17/2011 | BKCV | S&P affirms L-1 Identity
|
| 9/21/2010 | BKCV | Moody's confirms L-1 Identify
|
| 9/21/2010 | BKCV | S&P: L-1 on developing watch
|
| 9/20/2010 | CV | Market Commentary: Lennar higher on positive earnings report; L-1 Identity to par on merger news; CBIZ to price
|
| 8/31/2010 | BKCV | S&P keeps L-1 Identity on developing watch
|
| 7/7/2010 | BKCV | Moody's lowers L-1 Identity
|
| 6/23/2010 | BKCV | S&P puts L-1 Identity on developing watch
|
| 1/12/2010 | BKCV | S&P drops L-1 Identity
|
| 12/22/2009 | BKCV | Moody's affirms L-1 Identity
|
| 9/4/2008 | BKCV | Moody's ups L-1 Identity to SGL-2
|
| 7/16/2008 | BKCV | Moody's rates L-1 Identity loans Ba3
|
| 7/15/2008 | BKCV | S&P assigns L-1, convertibles BB-, loan BB+
|
| 5/17/2007 | CV | L-1 greenshoe exercised, increasing 3.75% convertibles to $175 million
|
| 5/11/2007 | CV | New Issue: L-1 prices $150 million 20-year convertibles near cheap end to yield 3.75%, up 60%
|
| 5/11/2007 | CV | Market Commentary: CACI climbs in debut; L-1 rises despite borrow concerns; Amgen slips further; Conseco gains on sentiment
|
| 5/10/2007 | CV | Market Commentary: Amgen falls under drug panel scrutiny; Alesco, Chesapeake gain early, end flat; CACI, L-1 quiet in gray
|
| 5/9/2007 | CV | L-1 talks $150 million 20-year convertibles at 3.25%-3.75%, up 57.5%-62.5%, to price Thursday
|
| 5/9/2007 | CV | Market Commentary: Chemed, Sciele soar in debuts; Alesco quiet in gray, Chesapeake draws mixed views; CACI, L-1 plan deals
|
